Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SHR-A1811 Combined With Bevacizumab in HER2-positive Breast Cancer With Brain Metastases
NCT06361979Phase 2Not yet recruiting
- Start
- May 2024
- Primary completion
- May 2025
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
01
Overview
A Phase 2 trial of trastuzumab rezetecan in breast cancer. Planned start May 2024; status: not yet recruiting.
02
Drugs
trastuzumab rezetecan
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT06361979.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06361979.